GR3021744T3 - Receptor ligands - Google Patents

Receptor ligands

Info

Publication number
GR3021744T3
GR3021744T3 GR960403147T GR960403147T GR3021744T3 GR 3021744 T3 GR3021744 T3 GR 3021744T3 GR 960403147 T GR960403147 T GR 960403147T GR 960403147 T GR960403147 T GR 960403147T GR 3021744 T3 GR3021744 T3 GR 3021744T3
Authority
GR
Greece
Prior art keywords
diiodo
benzofuran
pct
diethylaminoethoxy
benzoyl
Prior art date
Application number
GR960403147T
Other languages
English (en)
Inventor
Ulf Norinder
Juergen Bajorath
Jay F Stearns
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20382770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3021744(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Karobio Ab filed Critical Karobio Ab
Publication of GR3021744T3 publication Critical patent/GR3021744T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR960403147T 1991-05-17 1996-11-20 Receptor ligands GR3021744T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9101509A SE9101509D0 (sv) 1991-05-17 1991-05-17 Receptor ligands
PCT/SE1992/000307 WO1992020331A1 (en) 1991-05-17 1992-05-12 Receptor ligands

Publications (1)

Publication Number Publication Date
GR3021744T3 true GR3021744T3 (en) 1997-02-28

Family

ID=20382770

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960403147T GR3021744T3 (en) 1991-05-17 1996-11-20 Receptor ligands

Country Status (13)

Country Link
US (2) US5567728A (el)
EP (1) EP0584186B1 (el)
JP (1) JPH06507619A (el)
KR (1) KR100235778B1 (el)
AT (1) ATE141504T1 (el)
AU (1) AU660681B2 (el)
CA (1) CA2109625C (el)
DE (1) DE69213003T2 (el)
DK (1) DK0584186T3 (el)
ES (1) ES2090642T3 (el)
GR (1) GR3021744T3 (el)
SE (1) SE9101509D0 (el)
WO (1) WO1992020331A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316487B1 (en) 1993-06-16 2001-11-13 Aryx Therapeutics Compounds for treatment of cardiac arrhythmia synthesis, and methods of use
US5364880A (en) * 1993-06-16 1994-11-15 Advanced Therapies, Inc. Compound for treatment of cardiac arrhythmia, synthesis, and methods of use
GB9416219D0 (en) * 1994-08-11 1994-10-05 Karobio Ab Receptor ligands
JP2002514636A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性または高血糖症の治療に有用なフェニルオキソ−酢酸類
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
EP1408958A1 (en) * 2001-07-20 2004-04-21 Karo Bio Ab Benzofuranes and their use in the treatment of atrial fibrillation
EP1904502B1 (en) 2005-07-15 2009-10-21 Aryx Therapeutics, Inc. Antiarrhythmic precursor compounds, methods of synthesis and methods of use
US8454682B2 (en) 2010-04-13 2013-06-04 Medtronic Vascular, Inc. Anchor pin stent-graft delivery system
KR20230050232A (ko) * 2021-10-07 2023-04-14 주식회사 이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
CN118496183A (zh) * 2024-04-23 2024-08-16 山东济坤生物制药有限公司 一种盐酸胺碘酮杂质f的合成方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3248401A (en) * 1966-04-26 Diethylaminoe hoxybenzoyl benzofurans
FR1224490A (fr) * 1959-05-14 1960-06-24 Du Pont Nouvelles matières thermoplastiques et leur procédé de fabrication
US3880891A (en) * 1973-09-21 1975-04-29 Smithkline Corp Substituted benzofurans
GB1495680A (en) * 1975-06-20 1977-12-21 May & Baker Ltd 1-(2-benzoylphenoxy)-2-hydroxy-3-aminopropanes
JPH02304022A (ja) * 1989-05-18 1990-12-17 Mitsubishi Kasei Corp セロトニン拮抗剤

Also Published As

Publication number Publication date
EP0584186B1 (en) 1996-08-21
DE69213003D1 (de) 1996-09-26
AU1774392A (en) 1992-12-30
CA2109625C (en) 2000-03-28
SE9101509D0 (sv) 1991-05-17
DE69213003T2 (de) 1997-02-06
KR100235778B1 (ko) 1999-12-15
DK0584186T3 (da) 1996-09-09
ATE141504T1 (de) 1996-09-15
US5585404A (en) 1996-12-17
WO1992020331A1 (en) 1992-11-26
AU660681B2 (en) 1995-07-06
US5567728A (en) 1996-10-22
JPH06507619A (ja) 1994-09-01
ES2090642T3 (es) 1996-10-16
EP0584186A1 (en) 1994-03-02

Similar Documents

Publication Publication Date Title
GR3021744T3 (en) Receptor ligands
TW200607510A (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
HUP9801777A2 (hu) D2 vagy D4 vitamin-származékok alkalmazása a mellékpajzsmirigy túlműködés kezelésére szolgáló gyógyászati készítmények előállítására
NO952890D0 (no) Kombinasjonsbehandling for inhibisjon av bentap
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
RU94045155A (ru) Способы ингибирования болезни альцгеймера
LU92154I2 (fr) Axitinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
MY109265A (en) A salt of 3-[2-(diamethylamino) ethyl]-n-methyl-1h-indole-5-methanesulphonamide
BG104727A (en) Pharmaceutical composition of topiramate
CA2252515A1 (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
MY102565A (en) Novel derivatives of guanine
HUP9900905A2 (hu) D4-Vitamin származékok alkalmazása rák kezelésére szolgáló gyógyászati készítmények előállítására
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
GR3031356T3 (en) Neuroprotective chroman compounds
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
Burdick et al. Chronic pancreatitis: selection of patients for endoscopic therapy
IL112288A0 (en) Application of riluzole in the treatment of mitochondrial diseases
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
TW427978B (en) Tetrahydroisoquinoline derivatives
KR960705791A (ko) 기억력 향상제로서 유용한 3-아릴-4-알킬 및 4,5-디알킬-4H-1,2,4-트리아졸(3Aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles useful as memory enhancers)
TW362097B (en) 3-Phenyl-1, 4-dialkyl-1,2,4-triazolium salts and their use as antidepressants
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease